Takeda to sell TachoSil surgical patch to Corza Health for 350m euros

Published Wed, Sep 16, 2020 · 08:04 AM

[TOKYO] Takeda Pharmaceutical said on Wednesday it would sell its TachoSil surgical patch product to Corza Health for 350 million euros (S$563.7 million) as the Japanese company continues to divest non-core businesses.

TachoSil, a surgical patch used for bleeding control, delivered US$160 million in sales for Takeda in the fiscal year ended March 31, 2020, the company said in a release.

To reduce debt, Takeda has pledged to dispose of US$10 billion worth of non-core assets.

Takeda is focusing on five key business areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.

REUTERS

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes

Consumer & Healthcare

Dying salmon trouble Norway’s vast fish-farm industry
Fast-fashion giant Shein wants to sell skincare, toothpaste and toys, too
Billionaire Geiger is said to near US$7 billion L’Occitane buyout
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein

Companies & Markets

Takeda to sell TachoSil surgical patch to Corza Health for 350m euros

Consumer & Healthcare

Dying salmon trouble Norway’s vast fish-farm industry

Fast-fashion giant Shein wants to sell skincare, toothpaste and toys, too

Billionaire Geiger is said to near US$7 billion L’Occitane buyout

HCA beats first-quarter profit estimates on higher patient admissions

US FDA approves Pfizer’s gene therapy for rare bleeding disorder

EU toughens rules on Chinese fashion retailer Shein

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

SECTIONS

LIFESTYLE

Follow BT